Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations

Review article

Summary

Though chemotherapy remains a mainstay of non-small cell lung cancer (NSCLC) treatment, its efficacy has probably reached a plateau. The management of advanced NSCLC has evolved considerably in recent years due to a progressive understanding of tumour biology and the identification of promising molecular targets. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), a key signalling protein in tumour neoangiogenesis, growth and dissemination. The finding in study E4599 of a survival benefit for carboplatin-paclitaxel plus bevacizumab over chemotherapy alone led the U.S. FDA to approve the novel combination for the first-line treatment of patients with advanced, non-squamous NSCLC. This study is the first to show a survival advantage with the addition of a targeted agent to chemotherapy in this setting: in particular, for the first time the survival of NSCLC patients has been extended beyond one year. Recently, in a randomised phase III trial, patients receiving cisplatin-gemcitabine plus bevacizumab experienced a significantly longer progression-free survival compared to the standard arm. Based on these data, the EMEA has just issued a positive opinion to extend the drug's indication to include first-line treatment – in combination with any platinum-based chemotherapy – of advanced, non-squamous NSCLC. The aim of this review is to provide an overview of the evidence supporting the emergence of this new treatment. Key questions – including the optimal dose of bevacizumab, safety of the drug in special populations, the selection of patients most likely to benefit from the treatment, the role of maintenance – are addressed.

Keywords

Advanced non-small cell lung cancer Angiogenesis Bevacizumab Chemotherapy Targeted therapies 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol, 18(3): 581–592, 2007PubMedCrossRefGoogle Scholar
  2. Reck M, Gatzemeier U. Chemotherapy in stage IV NSCLC. Lung Cancer, 45(Suppl 2): S217–S222, 2004PubMedCrossRefGoogle Scholar
  3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353: 123–132, 2005PubMedCrossRefGoogle Scholar
  4. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 22: 2184–2191, 2004PubMedCrossRefGoogle Scholar
  5. Pujol JL, Barlesi F, Daures JP. Should chemotherapy combinations for advanced non small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer, 51: 335–345, 2006PubMedCrossRefGoogle Scholar
  6. Herbst RS, Takeuchi H, Teicher BA. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother Pharmacol, 41: 497–504, 1998PubMedCrossRefGoogle Scholar
  7. Sandler A, Gray R, Perry MC, et al. Paclitaxel carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 355: 2542–2550, 2006PubMedCrossRefGoogle Scholar
  8. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol, 25(18S): LBA7514, 2007Google Scholar
  9. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest, 116: 2610–2621, 2006PubMedCrossRefGoogle Scholar
  10. Green MR. Targeting targeted therapy. N Engl J Med, 350: 2191–2193, 2004PubMedCrossRefGoogle Scholar
  11. Herbst RS, Lippman SM. Molecular signatures of lung cancer-toward personalized therapy. N Engl J Med, 356: 76–78, 2007PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • F. Grossi
    • 1
  • A. Brianti
    • 1
  • C. Defferrari
    • 1
  • P. Pronzato
    • 1
  1. 1.Medical Oncology A, Disease Management Team – Lung Cancer, National Institute for Cancer ResearchGenovaItaly

Personalised recommendations